Patents Assigned to SeeCure Taiwan Co., Ltd.
-
Publication number: 20230226230Abstract: A compound for measurement of thiopurine pathway directed systems imaging and therapy including a chelator and a thiopurine ligand is provided. A method of synthesizing the compound is also provided, and the compound may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.Type: ApplicationFiled: February 26, 2021Publication date: July 20, 2023Applicant: SEECURE TAIWAN CO., LTD.Inventors: Wei-Chung CHANG, David J. YANG, Min-Ching CHUNG, Chi-Shiang KE, Tsung-Tien KUO
-
Patent number: 11090395Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.Type: GrantFiled: September 14, 2018Date of Patent: August 17, 2021Assignee: SeeCure Taiwan Co., Ltd.Inventors: Tsung-Tien Kuo, David J. Yang, Wei-Chung Chang, Min-Ching Chung, Chi-Shiang Ke
-
Publication number: 20210196655Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.Type: ApplicationFiled: March 4, 2021Publication date: July 1, 2021Applicant: SeeCure Taiwan Co., Ltd.Inventors: Tsung-Tien Kuo, David J. Yang, Wei-Chung Chang, Min-Ching Chung, Chi-Shiang Ke
-
Publication number: 20200085978Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.Type: ApplicationFiled: September 14, 2018Publication date: March 19, 2020Applicant: SeeCure Taiwan Co., Ltd.Inventors: Tsung-Tien Kuo, David J. Yang, Wei-Chung Chang, Min-Ching Chung, Chi-Shiang Ke
-
Publication number: 20180326101Abstract: A compound represented by formula (I) is provided, wherein in formula (I), R1 and R2 each independently represents hydrogen, O—R3 or S—R4, at least one of R1 and R2 is O—R3 or S—R4, and R3 and R4 are independently a C1 to C10 alkyl group, such that the C1 to C10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of —OH, —NH2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents.Type: ApplicationFiled: May 11, 2017Publication date: November 15, 2018Applicant: SeeCure Taiwan Co., Ltd.Inventors: Ning Tsao, Wei-Chung Chang
-
Publication number: 20180296707Abstract: A pharmaceutical formulation including a chelator-somatostatin receptor ligand and a transchelator is provided. The chelator-somatostatin receptor ligand is conjugated with a metal source or a radionuclide source, whereas the transchelator is capable of capturing free metal source or radionuclide source that is not conjugated to the chelator-somatostatin receptor ligand. By using such pharmaceutical formulation, the preparation of radiolabeled somatostatin analogues could be made more efficient, and is feasible for imaging of SSTR pathway-activated systems in cancers and neurological diseases.Type: ApplicationFiled: April 12, 2017Publication date: October 18, 2018Applicant: SeeCure Taiwan Co., Ltd.Inventors: Ning Tsao, Tsung-Tien Kuo, David J. Yang
-
Publication number: 20180264125Abstract: A glycopeptide composition including a plurality of glycopeptides and a therapeutic agent or diagnostic compound is provided. Each of the glycopeptide includes a polysaccharide moiety connected to a peptide moiety, and the polysaccharide moiety is covalently bounded to the peptide moiety via a fixed connection point, wherein the fixed connection point is the same in each of the glycopeptide, and the therapeutic agent or diagnostic is conjugated to each of the glycopeptide.Type: ApplicationFiled: February 12, 2018Publication date: September 20, 2018Applicant: SeeCure Taiwan Co., Ltd.Inventors: Ning Tsao, Wei-Chung Chang
-
Publication number: 20180193494Abstract: A compound represented by formula (I) is provided, wherein in formula (I), R1 and R2 each independently represents hydrogen, O—R3 or S—R4, at least one of R1 and R2 is O—R3 or S—R4, and R3 and R4 are independently a C1 to C10 alkyl group, such that the C1 to C10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of —OH, —NH2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents.Type: ApplicationFiled: January 9, 2017Publication date: July 12, 2018Applicant: SeeCure Taiwan Co., Ltd.Inventors: Wei-Chung Chang, Kun-Hsin Lee, Kai-Chi Chang, Ping-Fan Chen, Min-Huei Huang, Hung-Yuan Huang, Ning Tsao
-
Patent number: 10016520Abstract: A compound represented by formula (I) is provided, wherein in formula (I), R1 and R2 each independently represents hydrogen, O—R3 or S—R4, at least one of R1 and R2 is O—R3 or S—R4, and R3 and R4 are independently a C1 to C10 alkyl group, such that the C1 to C10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of —OH, —NH2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents.Type: GrantFiled: January 9, 2017Date of Patent: July 10, 2018Assignee: SeeCure Taiwan Co., Ltd.Inventors: Wei-Chung Chang, Kun-Hsin Lee, Kai-Chi Chang, Ping-Fan Chen, Min-Huei Huang, Hung-Yuan Huang, Ning Tsao